Stopping pandemics before they start: Lessons learned from SARS-CoV-2

Science. 2022 Mar 11;375(6585):1133-1139. doi: 10.1126/science.abn1900. Epub 2022 Mar 10.

Abstract

The vaccine and drug discovery responses to COVID-19 have worked far better than could have been imagined. Yet by the end of 2021, more than 5 million people had died, and the pandemic continues to evolve and rage globally. This Review will describe how each of the vaccines, antibody therapies, and antiviral drugs that have been approved to date were built on decades of investment in technology and basic science. We will caution that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has so far proven a straightforward test of our pandemic preparedness, and we will recommend steps we should undertake now to prepare for, to minimize the effects of, and ideally to prevent future pandemics. Other Reviews in this series describe the interactions of SARS-CoV-2 with the immune system and those therapies that target the host response to infection.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antiviral Agents / therapeutic use*
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / immunology
  • Disease Progression
  • Drug Development
  • Drug Discovery
  • Humans
  • Pandemics / prevention & control*
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / immunology*
  • Vaccine Development
  • Vaccinology
  • Viral Vaccines / immunology
  • Virus Diseases / drug therapy
  • Virus Diseases / prevention & control

Substances

  • Antibodies, Monoclonal
  • Antiviral Agents
  • COVID-19 Vaccines
  • Viral Vaccines

Supplementary concepts

  • SARS-CoV-2 variants